Pathogenetic relevance of mutations in the Transthyretin gene in patients with polyneuropathy

Pathogenetic relevance of mutations in the Transthyretin gene in patients with polyneuropathy - PARMITTYR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00018881

Enrollment

300

Registered

2020-06-30

Start date

2020-07-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic polyneuropathy

Interventions

Group 1: Patient with idiopathic polyneuropathy. 2 Additional blood samples (EDTA) during routinely blood samples

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18-years old with idiopathic polyneuropathy

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
Is there a mutation in the TTR gene?	—

Secondary

Measure	Time frame
Are there elecrtophysiologic or biochemic aberrations?	—

Countries

Germany

Contacts

Public ContactH.C. Lehmann

Uniklinik Köln

helmar.lehmann@uk-koeln.de+49-221-478-87091

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026